HR001 was uncovered to possess an efficacious response for clients with relapsed/refractory non-Hodgkin lymphoma. Experimental: Dose expansion_sub-populace 2_lower dose of niraparib MTDs and/or applicant RP2Ds for elimusertib employed in combination with niraparib at a decrease fixed dose. On the other hand, owing to varied objective factors, there is a reduced https://muqtaday111kvg3.losblogos.com/profile